ACLARION, INC. Other Selling and Marketing Expense
ACLARION, INC. (ACON) reported Other Selling and Marketing Expense of $124.76 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2023-08-25.
Discontinued › Operating Expenses
us-gaap:OtherSellingAndMarketingExpense · last filed 2023-08-25
- ACLARION, INC. other selling and marketing expense for the quarter ending 2022-06-30 was $124.76K.
| Period end | Other Selling and Marketing Expense 3 month | Other Selling and Marketing Expense 6 month |
|---|---|---|
| 2022-06-30 | $124.76K 10-Q · filed 2023-08-25 | $194.07K 10-Q · filed 2023-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |